Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Varenicline · Chantix, Tyrvaya

Small molecule · Agonist of alpha-4 beta-2 neuronal nicotinic acetylcholine receptor (CHRNA4) · developed by Pf Prism Cv

Approved FDA, May 2006
1 Registered trials

What is Varenicline?

Varenicline is a small-molecule partial agonist that binds with high selectivity to alpha-4 beta-2 neuronal nicotinic acetylcholine receptors, producing weaker receptor activity than nicotine while blocking nicotine from activating them. It also binds with moderate affinity to the 5-HT3 receptor. Varenicline is studied in dry eye disease as a nasal spray formulation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Chantix, Tyrvaya
Drug type
Small molecule
Targets
alpha-4 beta-2 neuronal nicotinic acetylcholine receptor (CHRNA4), 5-HT3 receptor (HTR3A) (secondary target)
Mechanism
Agonist of alpha-4 beta-2 neuronal nicotinic acetylcholine receptor (CHRNA4)
Pathways
central nervous mesolimbic dopamine system stimulation, nicotine-induced receptor activation blockade
Therapy area
Ophthalmology
Developer
Pf Prism Cv
In trials of
OCUL
FDA status
Approved as Chantix, Tyrvaya (May 10, 2006), NDA021928 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 1, 2020). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07705893 N/A Dry Eye Recruiting OCUL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Dry Eye

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.